Spotlight

Around the Practice

Between the Lines

Contemporary Concepts

Journal

OncView

Podcasts

Readout 360

2022 ASCO Genitourinary Cancers Symposium Urothelial Cancer Updates

CancerNetwork® Inaugural Face-Off

Contemporary Concepts in Hematologic Oncology

Insights from Experts at Mayo Clinic on Translating Evidence to Clinical Practice

Optimizing Outcomes in Patients with HER2+ Metastatic Breast Cancer

Clinical

Acute Myeloid Leukemia

Brain Cancer

Breast Cancer

Gastrointestinal Cancer

Genitourinary Cancer

Gynecologic Cancer

Hematology

Leukemia

Lung Cancer

Lymphoma

Pediatric Cancers

Skin Cancer

Clinical Topics

Integrative Care

Global Bulletin

All News

Approval Alert

2 Minute Drill

Around the Practice

Between the Lines

Clinical Consult

Expert Interviews

Face Off

Medical World News

Morning Rounds

OncView

Podcasts

Readout 360

Satellite Sessions

Kun He, PhD

home / authors / kun-he-phd

Articles

Liposomal Doxorubicin in Combination With Bortezomib for Relapsed or Refractory Multiple Myeloma

November 1st 2007

Liposomal doxorubicin received FDA approval for use in combination with bortezomib in patients with multiple myeloma who have not previously received bortezomib and have received at least one prior therapy.

Do Not Sell My Personal Information

Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777